Table 4.
The Top 20 enrichment pathways of 195 major hubs.
| Term | Count | Value |
|---|---|---|
| hsa05200: Pathways in cancer | 70 | 2.22E-41 |
| hsa04010: MAPK signaling pathway | 34 | 5.88E-12 |
| hsa05220: Chronic myeloid leukemia | 29 | 9.85E-24 |
| hsa04062: Chemokine signaling pathway | 28 | 1.71E-11 |
| hsa04510: Focal adhesion | 28 | 9.51E-11 |
| hsa05215: Prostate cancer | 27 | 5.69E-19 |
| hsa04722: Neurotrophin signaling pathway | 27 | 4.59E-15 |
| hsa04012: ErbB signaling pathway | 26 | 4.46E-18 |
| hsa04060: Cytokine-cytokine receptor interaction | 26 | 5.61E-07 |
| hsa05210: Colorectal cancer | 23 | 4.84E-15 |
| hsa05221: Acute myeloid leukemia | 22 | 1.16E-17 |
| hsa04620: Toll-like receptor signaling pathway | 22 | 2.94E-12 |
| hsa04660: T cell receptor signaling pathway | 22 | 1.16E-11 |
| hsa04650: Natural killer cell mediated cytotoxicity | 22 | 7.02E-10 |
| hsa04630: Jak-STAT signaling pathway | 22 | 1.23E-08 |
| hsa05212: Pancreatic cancer | 20 | 3.49E-13 |
| hsa04664: Fc epsilon RI signaling pathway | 19 | 1.82E-11 |
| hsa04910: Insulin signaling pathway | 19 | 1.88E-07 |
| hsa05214: Glioma | 18 | 4.43E-12 |
| hsa04110: Cell cycle | 18 | 3.16E-07 |